These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 25133286)

  • 1. Why are cancer drugs so costly?
    Clin Adv Hematol Oncol; 2014 Jan; 12(1):62. PubMed ID: 25133286
    [No Abstract]   [Full Text] [Related]  

  • 2. Without rewards, the cycle of innovation would stop.
    Crenshaw NF
    Clin Adv Hematol Oncol; 2014 Jan; 12(1):63. PubMed ID: 25129903
    [No Abstract]   [Full Text] [Related]  

  • 3. Short-term costs can lead to long-term gain.
    Howard P
    Clin Adv Hematol Oncol; 2014 Jan; 12(1):66. PubMed ID: 25129909
    [No Abstract]   [Full Text] [Related]  

  • 4. Impressive gains with innovative medicines.
    Chin B
    Clin Adv Hematol Oncol; 2014 Jan; 12(1):65. PubMed ID: 25129907
    [No Abstract]   [Full Text] [Related]  

  • 5. Charging what the market will bear is inappropriate.
    Kantarjian HM
    Clin Adv Hematol Oncol; 2014 Jan; 12(1):63. PubMed ID: 25129904
    [No Abstract]   [Full Text] [Related]  

  • 6. The system over-rewards incremental gains.
    Saltz L
    Clin Adv Hematol Oncol; 2014 Jan; 12(1):64. PubMed ID: 25129906
    [No Abstract]   [Full Text] [Related]  

  • 7. Investment fund established to combat cancer drug 'development gap'.
    Hemsley A
    Future Med Chem; 2012 May; 4(8):948. PubMed ID: 22826901
    [No Abstract]   [Full Text] [Related]  

  • 8. The era of cancer discovery.
    Cantley LC; Baselga J
    Cancer Discov; 2011 Jun; 1(1):1. PubMed ID: 22586302
    [No Abstract]   [Full Text] [Related]  

  • 9. Budget cuts and the plight of postdocs.
    Goozner M
    J Natl Cancer Inst; 2013 Feb; 105(3):153-4. PubMed ID: 23334223
    [No Abstract]   [Full Text] [Related]  

  • 10. Discontinued drugs in 2010: oncology drugs.
    Williams R
    Expert Opin Investig Drugs; 2011 Nov; 20(11):1479-96. PubMed ID: 21955127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlling the cost of innovative cancer therapeutics.
    Malik NN
    Nat Rev Clin Oncol; 2009 Sep; 6(9):550-2. PubMed ID: 19707244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of new cancer drugs in real practice oncology: a monoinstitutional experience.
    Jirillo A; Imbevaro S; Mazurek M
    Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):702-5. PubMed ID: 22239469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eliminate cost-plus reimbursement for drugs.
    Conti RM
    Clin Adv Hematol Oncol; 2014 Jan; 12(1):66. PubMed ID: 25129910
    [No Abstract]   [Full Text] [Related]  

  • 14. Greater effectiveness for the same cost.
    Kolchinsky P
    Clin Adv Hematol Oncol; 2014 Jan; 12(1):64. PubMed ID: 25129905
    [No Abstract]   [Full Text] [Related]  

  • 15. Developing new anti-cancer drugs.
    Pereira Rde S
    Recent Pat Anticancer Drug Discov; 2011 Jan; 6(1):1-5. PubMed ID: 21110819
    [No Abstract]   [Full Text] [Related]  

  • 16. Outpatient cancer drug costs: changes, drivers, and the future.
    Halbert RJ; Zaher C; Wade S; Malin J; Lawless GD; Dubois RW
    Cancer; 2002 Feb; 94(4):1142-50. PubMed ID: 11920485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Importance of Economic Trade-offs in Cancer Drug Pricing.
    Fonseca R; Peneva D; Clancy Z; Abouzaid S; Jena AB
    Mayo Clin Proc; 2018 Aug; 93(8):976-979. PubMed ID: 29945732
    [No Abstract]   [Full Text] [Related]  

  • 18. Waste and missed opportunities drive costs upward.
    Davis W
    Clin Adv Hematol Oncol; 2014 Jan; 12(1):65. PubMed ID: 25129908
    [No Abstract]   [Full Text] [Related]  

  • 19. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
    Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
    J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The real worth of cancer drugs.
    The Lancet Oncology
    Lancet Oncol; 2020 Dec; 21(12):1537. PubMed ID: 33271083
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.